Caza T, et al.. NELL1 is a target antigen in malignancy-associated membranous nephropathy. Kidney Int [published online ahead of print August 20, 2020]. doi: 10.1016/j.kint.2020.07.039

Caza T, . NELL1 is a target antigen in malignancy-associated membranous nephropathy. Kidney Int [published online ahead of print August 20, 2020]. doi: 10.1016/j.kint.2020.07.039)| false
• Search Google Scholar
• Export Citation

Sethi S, et al.. Exostosin 1/exostosin 2-associated membranous nephropathy. J Am Soc Nephrol 2019; 30:1123–1136. doi: 10.1681/ASN.2018080852

• Crossref
Sethi S, . Exostosin 1/exostosin 2-associated membranous nephropathy. J Am Soc Nephrol 2019; 30:1123–1136. doi: 10.1681/ASN.201808085210.1681/ASN.2018080852)| false
• Search Google Scholar
• Export Citation

Fervenza FC, et al.. MENTOR Investigators. Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med 2019; 381:36–46. doi: 10.1056/NEJMoa1814427

• Crossref
Fervenza FC, . MENTOR Investigators. Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med 2019; 381:36–46. doi: 10.1056/NEJMoa181442710.1056/NEJMoa1814427)| false
• Search Google Scholar
• Export Citation

Fernández-Juárez G, et al.. STARMEN Investigators. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. Kidney Int [published online ahead of print November 7, 2020]. doi: 10.1016/j.kint.2020.10.014

Fernández-Juárez G, . STARMEN Investigators. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. Kidney Int [published online ahead of print November 7, 2020]. doi: 10.1016/j.kint.2020.10.014)| false
• Search Google Scholar
• Export Citation

Delbarba E, et al.. Rituximab vs. cyclosphosphamide in the treatment of membranous nephropathy: The RI-CYCLO trial. Presented as Poster PO2638 at Kidney Week Reimagined virtual conference, October 19–25, 2020.

Delbarba E, . Rituximab vs. cyclosphosphamide in the treatment of membranous nephropathy: The RI-CYCLO trial. Presented as Poster PO2638 at Kidney Week Reimagined virtual conference, October 19–25, 2020.)| false
• Search Google Scholar
• Export Citation

Furie R, et al.. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med 2020; 383:1117–1128. doi: 10.1056/NEJMoa2001180

• Crossref
Furie R, . Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med 2020; 383:1117–1128. doi: 10.1056/NEJMoa200118010.1056/NEJMoa2001180)| false
• Search Google Scholar
• Export Citation

Dooley MA, et al.. ALMS Group. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011; 365:1886–1895. doi: 10.1056/NEJMoa1014460

• Crossref
Dooley MA, . ALMS Group. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011; 365:1886–1895. doi: 10.1056/NEJMoa101446010.1056/NEJMoa1014460)| false
• Search Google Scholar
• Export Citation

Rovin BH, et al.. Management of lupus nephritis (LN) with voclosporin: An update from a pooled analysis of 534 patients. Presented as Poster PO1917 at Kidney Week Reimagined virtual conference, October 19–25, 2020.

Rovin BH, . Management of lupus nephritis (LN) with voclosporin: An update from a pooled analysis of 534 patients. Presented as Poster PO1917 at Kidney Week Reimagined virtual conference, October 19–25, 2020.)| false
• Search Google Scholar
• Export Citation

Rauen T, et al.. STOP-IgAN Investigators. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 2015; 373:2225–2236. doi: 10.1056/NEJMoa1415463

• Crossref
Rauen T, . STOP-IgAN Investigators. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 2015; 373:2225–2236. doi: 10.1056/NEJMoa141546310.1056/NEJMoa1415463)| false
• Search Google Scholar
• Export Citation

Lv J, et al.. TESTING Study Group. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: The TESTING randomized clinical trial. JAMA 2017; 318:432–442. doi: 10.1001/jama.2017.9362

• Crossref
Lv J, . TESTING Study Group. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: The TESTING randomized clinical trial. JAMA 2017; 318:432–442. doi: 10.1001/jama.2017.936210.1001/jama.2017.9362)| false
• Search Google Scholar
• Export Citation

Heerspink HJL, et al.. DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020; 383:1436–1446. doi: 10.1056/NEJMoa2024816

• Crossref
Heerspink HJL, . DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020; 383:1436–1446. doi: 10.1056/NEJMoa202481610.1056/NEJMoa2024816)| false
• Search Google Scholar
• Export Citation

Walsh M, et al.. PEXIVAS Investigators. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med 2020; 382:622–631. doi: 10.1056/NEJMoa1803537

• Crossref
Walsh M, . PEXIVAS Investigators. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med 2020; 382:622–631. doi: 10.1056/NEJMoa180353710.1056/NEJMoa1803537)| false
• Search Google Scholar
• Export Citation

Merkel PA, et al.. OP0011 A randomized, double-blind, active-controlled study of avacopan in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Ann Rheum Dis 2020; 79:8. doi: 10.1136/annrheumdis-2020-eular.1073

• Crossref
Merkel PA, . OP0011 A randomized, double-blind, active-controlled study of avacopan in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Ann Rheum Dis 2020; 79:8. doi: 10.1136/annrheumdis-2020-eular.107310.1136/annrheumdis-2020-eular.1073)| false
• Search Google Scholar
• Export Citation